The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis compared to other biologics in a real-world population.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients.‘ (Abstract number: 0290) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What did the ORAL surveillance study teach us about the safety profile of tofacitinib, compared to TNF-inhibitors? (0:26)
- What were the aims and design of your study? (1:24)
- What were the rates of treatment discontinuation of JAK inhibitors compared with other biologic therapies? (3:08)
- What were your conclusions in terms of the future use of JAK inhibitors? (5:05)
Disclosures: Kim Lauper discloses receiving grant/ research support from Galapagos, Eli Lilly, AbbVie, and Pfizer; serving on advisory boards for Pfizer; and participating in speaker’s bureaus for Viatris, Gilead-Galapgos, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
